Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 63, Issue 12, 2011, Pages 3942-3951

  Sreih, Antoine ^a,b   Ezzeddine, Rana ^c   Leng, Lin ^a   Lachance, Avery ^a   Yu, Geraldine ^a   Mizue, Yuka ^a   Subrahmanyan, Lakshman ^a   Pons Estel, Bernardo A ^d   Abelson, Anna Karin ^e   Gunnarsson, Iva ^f   Svenungsson, Elisabet ^f   Cavett, Joshua ^g   Glenn, Stuart ^g   Zhang, Lin ^a   Montgomery, Ruth ^a   Perl, Andras ^h   Salmon, Jane ⁱ   Alarcón Riquelme, Marta E ^e,g,j   Harley, John B ^k   Bucala, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Sanatorio Parque   (Argentina)

^e UPPSALA UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ HOSPITAL FOR SPECIAL SURGERY   (United States)

^j PTS Granada   (Spain)

^k CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MACROPHAGE MIGRATION INHIBITION FACTOR; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ETHNICITY; FEMALE; GENE EXPRESSION; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AFRICAN AMERICANS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82455198737     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30624     Document Type: Article

References (41)

1. Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16: 47-57.
2. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 311-8.
3. Barcellos LF, May SL, Ramsay PP, Quach HL, Lane JA, Nititham J, et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet 2009; 5: e1000696.
4. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40: 204-10. (Pubitemid 351171405)
5. Mitchell RA, Metz CN, Peng T, Bucala R,. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF): regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999; 274: 18100-6.
6. Calandra T, Bernhagen J, Mitchell RA, Bucala R,. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1895-902. (Pubitemid 24155670)
7. Hoi AY, Hickey MJ, Hall P, Yamana J, O'Sullivan KM, Santos LL, et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 2006; 177: 5687-96. (Pubitemid 44527645)
8. Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, et al. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol 2011; 186: 527-38.
9. Awandare GA, Martinson JJ, Were T, Ouma C, Davenport GC, Ong'echa JM, et al. MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. J Infect Dis 2009; 200: 629-37.
10. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005; 52: 3020-9. (Pubitemid 41447081)
11. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002; 3: 170-6. (Pubitemid 38961128)
12. Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M, et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 2004; 50: 1604-10. (Pubitemid 38608083)
13. Amoli MM, Donn RP, Thomson W, Hajeer AH, Garcia-Porrua C, Lueiro M, et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002; 29: 1671-3. (Pubitemid 34831240)
14. Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006; 54: 3661-9. (Pubitemid 44737179)
15. Mizue Y, Ghani S, Leng L, McDonald C, Kong P, Baugh J, et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A 2005; 102: 14410-5. (Pubitemid 41429711)
16. Nohara H, Okayama N, Inoue N, Koike Y, Fujimura K, Suehiro Y, et al. Association of the -173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 2004; 39: 242-6. (Pubitemid 38519429)
17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
18. Grigorenko EL, Han SS, Yrigollen CM, Leng L, Mizue Y, Anderson GM, et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 2008; 122: e438-45.
19. Zhong XB, Leng L, Beitin A, Chen R, McDonald C, Hsiao B, et al. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res 2005; 33: e121.
20. Zhao LP, Li SS, Khalid N,. A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies. Am J Hum Genet 2003; 72: 1231-50. (Pubitemid 36530010)
21. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2011.
22. Lee WC, Wang LY,. Simple formulas for gauging the potential impacts of population stratification bias. Am J Epidemiol 2008; 167: 86-9.
23. Barton A, Lamb R, Symmons D, Silman A, Thomson W, Worthington J, et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 2003; 4: 487-91. (Pubitemid 38967615)
24. Gao L, Flores C, Ma S, Miller EJ, Moitra J, Moreno L, et al. Macrophage migration inhibitory factor in acute lung injury: expression, biomarker and associations. Transl Res 2007; 150: 18-29. (Pubitemid 46935595)
25. De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003; 48: 1398-407. (Pubitemid 36554539)
26. Hopkinson ND, Doherty M, Powell RJ,. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis 1994; 53: 675-80. (Pubitemid 24330603)
27. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS,. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257-68.
28. Yende S, Angus DC, Kong L, Kellum JA, Weissfeld L, Ferrell R, et al. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J 2009; 23: 2403-11.
29. Sanchez E, Gomez LM, Lopez-Nevot MA, Gonzalez-Gay MA, Sabio JM, Ortego-Centeno N, et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun 2006; 7: 433-6. (Pubitemid 44111648)
30. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A 2002; 99: 345-50. (Pubitemid 34060365)
31. Studnicka-Benke A, Steiner G, Petera P, Smolen JS,. Tumour necrosis factor α and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-74.
32. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF,. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004; 31: 268-73. (Pubitemid 38160747)
33. Kim WU, Sreih A, Bucala R,. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev 2009; 8: 204-8.
34. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ,. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25: 417-28. (Pubitemid 44354217)
35. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33. (Pubitemid 37255038)
36. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO,. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990; 87: 1233-7.
37. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, et al. A molecular basis for MHC class II-associated autoimmunity [published erratum appears in Science 1988;241:888]. Science 1988; 240: 1003-9.
38. De Rycke L, Baeten D, Kruithof E, van den Bosch F, Veys EM, De Keyser F,. The effect of TNFα blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005; 14: 931-7. (Pubitemid 43088266)
39. Rahman A, Isenberg DA,. Mechanisms of disease: systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39. (Pubitemid 351397092)
40. White S, Rosen A,. Apoptosis in systemic lupus erythematosus. Curr Opin Rheumatol 2003; 15: 557-62. (Pubitemid 37041392)
41. Petrovsky N, McNair P, Harrison LC,. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine 1998; 10: 307-12. (Pubitemid 28227075)